文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌精囊腺受累患者中等大分割放疗的毒性与结局

Toxicity and Outcomes of Moderately Hypofractionated Radiation for Prostate Cancer With Seminal Vesicle Involvement.
PubMed 文献 · Adv Radiat Oncol · 2023-04-24

单中心研究将41例磁共振成像或临床检查证实精囊腺受累(SVI)并接受前列腺及单侧或双侧精囊腺中等大分割放疗(MHRT)的患者,按倾向性评分匹配82例同期仅前列腺放疗患者。SVI组计划靶体积更大、直肠最大点剂量和100%处方剂量体积更高,但2级及以上泌尿及肠道毒性累积发生率无差异,生化复发、前列腺癌特异性生存和总生存亦无差异。

要点

  • SVI组计划靶体积152.2 vs 109.9 cc(P < .001),直肠最大点剂量103.9% vs 102.8%(P = .030)。
  • 2级及以上泌尿毒性HR 0.73(95% CI 0.39-1.35;P = .31),肠道毒性HR 0.35(95% CI 0.04-3.03;P = .34)。
  • 生化复发、前列腺癌特异性生存和总生存两组间均无差异。

核心结论

  • 对局限期前列腺癌精囊腺受累按处方剂量行MHRT不增加肠道或泌尿毒性。
  • 伴或不伴SVI的患者观察到相似的临床结局。

研究设计与样本

  • 单中心研究纳入2013年至2021年接受前列腺及单侧或双侧精囊腺MHRT的41例SVI患者,按倾向性评分匹配82例同期仅前列腺放疗患者。
  • 比较计划靶体积、膀胱和直肠剂量学,按美国国家癌症研究所不良事件通用术语标准5.0版评估泌尿和肠道毒性。
  • 评估生化复发、前列腺癌特异性生存和总生存。

主要发现

  • 41例SVI患者中26.8%经临床检查发现SVI,95.1%为高危前列腺癌。
  • 与无SVI队列相比,包含SVI的治疗计划计划靶体积更大(152.2 vs 109.9 cc;P < .001)、最大点剂量更高(107.9% vs 105.8%;P < .001)、接受100%处方剂量的体积更大(143.1 vs 95.9 cc;P < .001)。
  • 两组膀胱剂量学变量无差异,但直肠最大点剂量(103.9% vs 102.8%;P = .030)和直肠接受100%处方剂量的体积(1.8 vs 1.2 cc;P = .016)增加。
  • 2级及以上泌尿毒性累积发生率无差异(HR 0.73;95% CI 0.39-1.35;P = .31),肠道毒性亦无差异(HR 0.35;95% CI 0.04-3.03;P = .34)。
  • 生化复发(HR 0.47;95% CI 0.16-1.38;P = .17)、前列腺癌特异性生存(HR 0.31;95% CI 0.04-2.49;P = .31)和总生存(HR 0.35;95% CI 0.10-1.16;P = .09)伴或不伴SVI均无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to assess the toxicity and outcomes following treatment of prostate cancer with seminal vesicle involvement (SVI) evident on magnetic resonance imaging or clinical examination with moderately hypofractionated radiation therapy (MHRT). METHODS AND MATERIALS: Forty-one patients treated with MHRT to the prostate and 1 or both seminal vesicles from 2013 to 2021 at a single institution were identified and propensity score matched to 82 patients treated during the same period with prescription dose given to the prostate alone. Dosimetry of the planning target volume, bladder, and rectum were compared. Urinary and bowel toxicity were scored by National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Clinical outcomes including freedom from biochemical recurrence, prostate cancer-specific survival, and overall survival were assessed. RESULTS: Of the 41 patients identified with SVI, 26.8% had SVI by clinical examination and 95.1% had high-risk prostate cancer. Compared with the cohort without SVI, treatment plans to include SVI had a larger planning target volume (152.2 vs 109.9 cc; P < .001), maximum point dose (107.9% vs 105.8%; P < .001), and volume receiving 100% of the prescription dose (143.1 vs 95.9 cc; P < .001). No difference in bladder dosimetric variables between cohorts was observed, but there was an increase in the rectal maximum point dose (103.9% vs 102.8%; P = .030) and rectal volume receiving 100% of the prescription dose (1.8 vs 1.2 cc; P = .016). Despite these differences, there was no difference in the cumulative incidence of grade 2+ urinary (hazard ratio [HR], 0.73; 95% CI, 0.39-1.35; P = .31) or bowel (HR, 0.35; 95% CI, 0.04-3.03; P = .34) toxicity. Freedom from biochemical recurrence (HR, 0.47; 95% CI, 0.16-1.38; P = .17), prostate cancer-specific survival (HR, 0.31; 95% CI, 0.04-2.49; P = .31), and overall survival (HR, 0.35; 95% CI, 0.10-1.16; P = .09) also did not differ with or without SVI, respectively. CONCLUSIONS: Treatment of SVI to prescription dose with MHRT for localized prostate cancer does not increase bowel or urinary toxicity. Similar clinical outcomes were also observed with or without SVI.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Acklin-Wehnert S, Carpenter D, Natesan D, et al. Toxicity and Outcomes of Moderately Hypofractionated Radiation for Prostate Cancer With Seminal Vesicle Involvement. Adv Radiat Oncol. 2023. PMID: 37408675. doi:10.1016/j.adro.2023.101252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。